Overview

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Status:
NOT_YET_RECRUITING

Trial end date:
2033-12-31

Target enrollment:

Participant gender:

Summary

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

BioNTech SE

Treatments:

durvalumab